Sudeep Pharma Q4 FY26 Results: PAT Rs 49 Cr
- May 22, 2026
- Posted by: Neeraj Pandey
- Category: News
Sudeep Pharma Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 49 crore for the quarter ended March 31, 2026, up 11.0% YoY compared to Rs 44 crore in Q4 FY25. Revenue from operations stood at Rs 182 crore, up 15.0% YoY. Results are on a Consolidated basis. Sudeep Pharma is a Pharmaceuticals company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Sudeep Pharma Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | 182 | 158 | +15.0% |
| Gross Profit | Rs 59 crore | 56 | +5.0% |
| Net Profit | 49 | 44 | +11.0% |
| Basis | Consolidated | ||
Note: Sudeep Pharma Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.
Sudeep Pharma Q4 FY26 Performance Analysis
The Sudeep Pharma Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Sudeep Pharma operates in the Pharmaceuticals sector, which benefited from India’s GDP growth above 6.5% in FY26.
Revenue of Rs 182 crore reflects steady business conditions in the Pharmaceuticals sector.
Screen the best stocks on the Univest Screener.
Key Factors Driving Sudeep Pharma Q4 FY26 Results
Revenue and Business Performance
it revenue of Rs 182 crore was up 15.0% YoY. Revenue momentum reflects steady demand in the Pharmaceuticals business.
Profitability and Margins
the business PAT of Rs 49 crore up 11.0% YoY. Sustaining profitability while scaling revenues remains the key management priority.
India Macro Backdrop
The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Pharmaceuticals sector saw strong tailwinds during this period.
FY27 Outlook
Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Pharmaceuticals sector continues to benefit from India’s long-term structural growth.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is Sudeep Pharma Q4 FY26 net profit?
Ans. Sudeep Pharma Q4 FY26 PAT of Rs 49 crore, up 11.0% YoY from Rs 44 crore in Q4 FY25. Results declared May 21, 2026, on a Consolidated basis.
What is Sudeep Pharma Q4 FY26 revenue?
Ans. Sudeep Pharma Q4 FY26 revenue from operations was Rs 182 crore, up 15.0% YoY. Verify from BSE/NSE filings.
When were Sudeep Pharma Q4 FY26 results declared?
Ans. Sudeep Pharma Q4 FY26 results were declared on May 21, 2026, at the board of directors meeting approving audited Q4 and FY26 financial statements.
Is Sudeep Pharma a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.
